Cal-Maine Foods heads into the final stretch of its fiscal year with short sellers quietly rebuilding positions — a signal that the market is recalibrating expectations after the company's extraordinary egg-price windfall shows signs of fading.
Short interest has climbed to nearly 13% of the free float, its highest reading in the 30-day lookback window. The move has been steady rather than sharp: shares short rose roughly 4% week-on-week and 4% over the past month, reaching around 5.55 million shares by April 28. That consistency matters. This isn't a one-day reshuffling — it reflects a measured, persistent decision by professional short sellers to press the trade. The ORTEX short score confirms the directional read, climbing to 68.7 as of April 28, up from 64.0 just two weeks prior. Days to cover run above 10, meaning any reversal would take meaningful time to unwind.
The borrow market, however, tells a less stressed story. Availability is not tight — borrow costs are running near 0.47% annualised, barely moved from recent weeks, and availability remains well off critical levels. That means the current short build is demand-driven, not a squeeze setup. Shorts are entering by choice, not because of any sudden scarcity of supply. Options positioning echoes the cautious tone: the put/call ratio is 1.25, modestly above its 20-day mean of 1.12, with a z-score just above 1. Not extreme, but directionally defensive.
Analysts have been consistently trimming targets. BMO Capital cut its price target to $80 from $85 in late March, maintaining a Market Perform. Stephens moved in the opposite direction a week earlier, lifting its target to $90 from $85 while staying at Equal-Weight. The net result is a tightly covered name — just a handful of ratings, with consensus technically at Buy but that label rests on a single buy recommendation from Benchmark, initiated in December. Goldman Sachs holds Neutral with a $98 target. The mean target sits roughly 15-20% above the current $77.28 close, but that gap has been compressing for months as analysts have ratcheted down targets from peaks above $100. Valuation gives the bears some support: the PE has drifted up to around 11.8x as earnings estimates erode — the EPS momentum rank sits in the bottom 17th percentile over 30 days and the 13th percentile over 90 days — suggesting the Street is still cutting forecasts.
The fundamental tension is straightforward. Cal-Maine's bull case rests on what the company did: net sales surged 72% to $1.1 billion in its strongest period, driven by egg prices spiking to $3.31 per dozen. Capacity expansion in prepared foods, chick hatching rates up 11% year-on-year, and eggs in incubators up 10% suggest management is reinvesting aggressively for the next cycle. The bear case is what's happening now: net sales have already fallen 19% in a subsequent quarter, EPS estimates have been revised lower, and the conventional egg flock is down 13.6% year-on-year. Egg prices are mean-reverting faster than the earnings base is adjusting. The factor score on the dividend ranks in the 99th percentile and EV/EBIT sits at a similarly extreme cheap reading, which is the value investor's counter-argument — but EPS surprise ranks at the 85th percentile, suggesting the company has been quietly beating a lowered bar.
On the institutional side, BlackRock holds the largest stake at 15.2% of shares, with Vanguard at 10.4% and Dimensional adding meaningfully — 300,000 shares in the most recent filing period. The top-10 institutional holders all reported positions as of March 31, suggesting the register is relatively fresh. Against that backdrop, the insider activity from January — a cluster of small scheduled sells across CEO, CFO, COO, and Chairman at $72.44 — is too routine and low-value to read as a signal, though the stock has since recovered above those levels to $77.28.
The next scheduled earnings event is July 21. Between now and then, the key variable to watch is whether egg spot prices stabilise or continue to retreat from their extraordinary highs — that data point, more than any analyst target revision, will determine whether the short rebuild at 13% of float has room to grow or starts to look crowded.
See the live data behind this article on ORTEX.
Open CALM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
